Sartorius Stedim Biotech SA
PAR:DIM
Intrinsic Value
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. [ Read More ]
The intrinsic value of one
DIM
stock under the Base Case scenario is
193.5
EUR.
Compared to the current market price of 203.4 EUR,
Sartorius Stedim Biotech SA
is
Overvalued by 5%.
Sartorius Stedim Biotech SA's market capitalization is 18.7B EUR.
DIM stock price is 203.4 EUR.
DIM stock (193.5 EUR) is 5% less than its price (203.4 EUR).
DIM stock price (203.4 EUR) is 27% less than its Relative Value (279.54 EUR). Open Relative Valuation
DIM has upside potential of 34% compared to the average analyst price target.
Open Wall St Estimates
DIM's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
DIM's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 5%.
DIM's Revenue has been growing by 8% per year for the last 3 years.
DIM has positive Net Income for the last twelve months.
DIM's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
DIM's Revenue has dropped by 19% over the past 12 months.
DIM has positive Free Cash Flow for the last twelve months.
DIM's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 19% to 5%.
DIM's D/E (Debt to Equity) is very low and is equal to 0.8.
DIM has positive three-year average ROIC (Return on Invested Capital): 19%. The company is efficient at using invested capital to generate operating income.
DIM has positive Operating Income for the last twelve months.
DIM's long-term assets (8B EUR) exceed its long-term liabilties (5B EUR).
DIM's ROE (Return on Equity) has significantly decreased in the last 3 years from 28% to 8%.
DIM's short-term assets (2B EUR) exceed its short-term liabilties (975m EUR).
DIM has positive Gross Profit for the last twelve months.
DIM has positive Net Debt. This means that the company has more debt (3B EUR) than cash and short-term investments (728m EUR).
DIM has very high three-year average ROE (Return on Equity): 32%. The company is very efficient at transforming stockholders' equity into net income.
DIM's Altman Z-Score is very high and is equal to 4.33.
DIM generates enough operating income (405m EUR) to cover interest payments on its debt (119m EUR).
Valuation Backtest
Sartorius Stedim Biotech SA
Run backtest to discover the historical profit from buying and selling
DIM
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Sartorius Stedim Biotech SA
Balance Sheet Decomposition
Sartorius Stedim Biotech SA
| Current Assets | 2.1B |
| Cash & Short-Term Investments | 727.7m |
| Receivables | 401.4m |
| Other Current Assets | 948.5m |
| Non-Current Assets | 6.4B |
| Long-Term Investments | 41m |
| PP&E | 1.7B |
| Intangibles | 4.6B |
| Other Non-Current Assets | 64.5m |
| Current Liabilities | 975.4m |
| Accounts Payable | 402.8m |
| Accrued Liabilities | 68.1m |
| Other Current Liabilities | 504.5m |
| Non-Current Liabilities | 3.6B |
| Long-Term Debt | 3.1B |
| Other Non-Current Liabilities | 553.6m |
Earnings Waterfall
Sartorius Stedim Biotech SA
|
Revenue
|
2.7B
EUR
|
|
Cost of Revenue
|
-1.5B
EUR
|
|
Gross Profit
|
1.2B
EUR
|
|
Operating Expenses
|
-762.5m
EUR
|
|
Operating Income
|
404.9m
EUR
|
|
Other Expenses
|
-150.2m
EUR
|
|
Net Income
|
254.7m
EUR
|
Free Cash Flow Analysis
Sartorius Stedim Biotech SA
DIM Profitability Score
Profitability Due Diligence
Sartorius Stedim Biotech SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Sartorius Stedim Biotech SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
DIM Solvency Score
Solvency Due Diligence
Sartorius Stedim Biotech SA's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Sartorius Stedim Biotech SA's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DIM Price Targets Summary
Sartorius Stedim Biotech SA
According to Wall Street analysts, the average 1-year price target for
DIM
is 272.5 EUR
with a low forecast of 207.05 EUR and a high forecast of 378 EUR.
Shareholder Return
DIM Price
Sartorius Stedim Biotech SA
| Average Annual Return | 37.1% |
| Standard Deviation of Annual Returns | 59.41% |
| Max Drawdown | -70% |
| Market Capitalization | 18.7B EUR |
| Shares Outstanding | 97 315 904 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Sartorius Stedim Biotech SA
Country
Industry
Market Cap
Dividend Yield
Description
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,409 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
DIM
stock under the Base Case scenario is
193.5
EUR.
Compared to the current market price of 203.4 EUR,
Sartorius Stedim Biotech SA
is
Overvalued by 5%.
You don't have any saved screeners yet
